The immune system remains seriously out-of-whack—in an inflammatory state of overactivation and impaired ...
ImmunityBio, Inc. is upgraded to Buy reflecting improving Anktiva data & potential label expansions in NMIBC and NSCLC. Read ...
KYOTO--Researchers at Kyoto University have identified a new approach to a type of colorectal cancer that is resistant to ...
The Immune Atlas identifies immune signatures in MM, enhancing outcome prediction and guiding personalized therapies by ...
Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...
QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
A brain parasite infects the very cells meant to stop it. Scientists now know how the body still manages to fight back.
ANKTIVA® plus checkpoint inhibitor (CPI) therapy demonstrated statistically significant immune restoration across two ...
A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising ...
3don MSN
T cells gain superior memory through new reprogramming method, boosting cancer-fighting abilities
Georgetown University's Lombardi Comprehensive Cancer Center researchers have identified a new way to reprogram T cells, ...
Scientists have uncovered a hidden battle between a widespread brain parasite and the immune cells tasked with destroying it. A parasite that can quietly persist in the human brain is capable of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback